Benitec Biopharma Appoints Edward Smith to the Board of Directors
HAYWARD, Calif., April 14, 2020 /PRNewswire/ --Benitec Biopharma, Inc., a successor entity to Benitec Biopharma Limited (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today announced the appointment of Edward Smith to the Board of Directors.
- HAYWARD, Calif., April 14, 2020 /PRNewswire/ --Benitec Biopharma, Inc., a successor entity to Benitec Biopharma Limited (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today announced the appointment of Edward Smith to the Board of Directors.
- Edward brings more than 20 years of experience in executive finance and operations leadership in the biotechnology industry to Benitec's Board of Directors.
- Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma, Inc. commented on Mr. Smith's appointment, "Edward's extensive background in finance and operations in the biotherapeutics space will make him an exceptional contributor to the Board.
- Benitec Biopharma, Inc. ("Benitec" or the "Company") is a development-stage biotechnology company focused on the advancement of novel genetic medicines, with headquarters in Hayward, California.